Global Fund Current Affairs

India Health Fund to boost research on TB, malaria

The India Health Fund (IHF) launched by Tata Trusts in collaboration with Global Fund in August 2016 has come forward to financially support innovations and technologies designed to combat tuberculosis (TB) and malaria.

The initiative aims to support new products and strategies that impact entire lifecycle of malaria and TB, from prevention to post-cure recovery. It has recently invited project proposals.

Key Facts

TB and malaria pose long-standing health challenges for India. These two diseases account for over 4.23 lakh deaths and around 15 million lab-confirmed cases every year. The IHF initiative will support individuals and organisations with already germinated innovative strategies, services, products, such that they become sustainable and scalable solutions in addressing TB and malaria.

The initiative is not a fellowship programme to do research from scratch. It is long-term exercise aligned with country’s goal of eliminating TB by 2025 and malaria by 2030. It will promote innovative solutions such that they are widely accessible and are affordable

The four areas of research under it are

  • Use of technology and data science to strengthen surveillance of TB and malaria, inform early warning systems and improve early detection and prompt treatment.
  • Promote robust molecular diagnostic facilities feasible for primary healthcare in low-resource settings;
  • Promote innovations on effective communication strategies that will prevent transmission of malaria and TB and enable people to protect themselves from diseases.
  • Research on innovative approaches to vector surveillance.


Cipla wins Rs 1170 cr tender from Global Fund to supply HIV drugs

Indian pharmaceutical giant, Cipla has been awarded $188.95 million (around Rs. 1,172 crore) Contract by Global Fund to supply ARV (anti-retroviral) drugs.

Cipla has been selected as a Panel Supplier for a supplier partnership agreement. This contract is effective from 1 January 2015 and will run for a period of three years i.e. till 2018.

ARV drugs will be made at Cipla’s manufacturing facilities in India which has been approved by various international regulatory agencies.

Earlier, Cipla had played a pioneering role in supplying cheaper HIV/AIDS treatment. In 2001, Cipla was first pharmaceutical company to offer ARV drugs at a fraction of the cost in Africa. Since then, it had offered a triple combination ARV at less than a dollar a day and has treated several million patients.

Cipla has been associated with Global Fund since 2002. It also one of the suppliers of Global Fund awarded with a long-term contract to supply anti-malarial drugs.

About Global Fund

It was established in 2002. It operates in a partnership model between governments, civil society, private sector and people to accelerate the end of diseases such as AIDS, tuberculosis and malaria.

It raises and invests nearly $4 billion annually to support its programs in more than 140 countries.